May 10, 2022 8:00 am EDT NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35
May 03, 2022 7:00 am EDT Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today
Apr 27, 2022 8:00 am EDT Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government
Apr 20, 2022 8:00 am EDT Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics
Apr 19, 2022 11:00 am EDT Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company’s Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities
Apr 18, 2022 4:00 pm EDT REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments
Apr 18, 2022 8:30 am EDT Heat Biologics’ Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility
Apr 14, 2022 12:35 pm EDT Heat Biologics’ Announces Planned Investor and Media Livestream Event to Discuss Latest Developments